These findings indicate that Bmi‐1 could promote angiogenesis in glioma via NF‐κB/VEGF‐C, further suggesting that NF‐κB/VEGF‐C‐dependent Bmi‐1 may represent a novel therapeutic target for antiangiogenic strategies aimed at glioma. This evidence concerns the gene NFKB1 and central nervous system cancer.